Video - Results from #40

ASCO 2021 VL

Search

Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - Scott Tagawa Details Scott Tagawa joins Alicia Morgans in a discussion on a Phase I study evaluating the tolerability of 225Ac-J591 in metastatic castration-resistant prostate cancer (mCRPC). This study was designed to determine the dose-limiting toxicity and the maximum tolerated dose of 225Ac-J591 in a single dose regimen of 225Ac-J591 that can be given without severe side effects. The initial dose-escalation portio...
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas Details In this conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD highlights the PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy has been found to improve overall survival in MIBC, but about half of patients...
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar Details The phase 3 JAVELIN Bladder 100 trial demonstrated that First-line maintenance therapy with avelumab + best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone, while the optimal timing for starting avelumab after completing first-line (1L) chemotherapy is still unknown. In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin...
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi Details In this conversation with Alicia Morgans, MD, MPH, Karim Fizazi shares trial results from the phase II ODENZA trial presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ODENZA is a French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metasta...
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland Details Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials. These data were presented at the ASCO 2021 Annual Meeting. The researchers examined 35,195 patients in...
Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal Details The TITAN Study is the pivotal phase III trial demonstrating the benefit of apalutamide in mHSPC. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Neeraj Agarwal, MD, presented the health-related quality of life (HRQoL) data from this final analysis after cross-over from the phase III TITAN trial. In this conversation with Alicia Morgans, MD, MPH, he highlights this data. T...